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Abstract:  Neoplasms  of  the  ovary  present  an  increasing  challenge  to  the  physician. 
Neoplastic ovarian cysts can resemble endometriomas in ultrasound imaging and need to 
be carefully considered in the differential diagnosis. We report the case of a woman with a 
strong family history of hereditary breast and ovarian cancer, who presented with a pelvic 
mass. The young girl refused oncogenetic counseling and genetic testing, even though she 
had  a  50%  a  priori  probability  of  being  a  BRCA1  mutation  carrier.  Pelvic  magnetic 
resonance imaging (MRI) and a comparative analysis of the serum concentration of HE-4 
and CA125 biomarkers  provided accuracy  and  sensitivity in  the diagnosis of a benign 
ovarian pathology. Based on this experience, we propose that the sensitivity of a screening 
program based on a HE4 and CA125 assay and MRI in high risk patients with mutations in 
the  BRCA1  and  BRCA2  genes  may  be  considered  a  useful  pre-operative  tool  for  the 
differential diagnosis of pelvic masses.  
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1. Introduction 
Ovarian cancer (OC) is the second most common form of gynecological cancer and the first cause 
of  death  from  gynecological  malignancy  in  the  western  hemisphere.  Epidemiologic  studies  have 
clearly established the role of family history as an important risk factor for OC and inherited, highly 
penetrant germline mutations of the BRCA1 and BRCA2 oncosuppressor genes are responsible for  
5–10% of the OC cases [1,2]. 
OC is often diagnosed at an advanced stage due to the absence of early symptoms and to the 
inadequacy  of  available  screening  methods,  resulting  in  a  low  survival  rate.  The  median  survival 
period  ranges  from  18  to  24  months  with  an  80%  probability  of  disease  recurrence  within  five 
years [3].  
Validation of  novel  biomarkers might  help  improving the specificity and sensitivity of ovarian 
cancer diagnosis. In example, studies on the Human epididymis specific protein 4 (HE4) alone or in 
combination with CA125 are being extensively carried out [4–8].  
Recently, we have shown that not only HE4 is expressed in the early stages of the disease, but it is 
also an early indicator of disease recurrence [9].  
In this case report, we applied the determination of serum concentrations of HE4 and CA 125 to the 
diagnosis of a pelvic mass that appeared in a young patient at high-risk for ovarian cancer due to her 
family history of breast cancer associated to a pathogenic BRCA1 gene mutation.  
2. Case Presentation and Discussion 
A 24-year-old woman with a strong family history of breast cancer, and potentially at risk for breast 
and ovarian cancer due to  a BRCA1 gene mutation (Q139X, Exon 7) discovered in  her relatives 
(Figure  1),  presented  to  our  institution  with  a  painful  pelvic  mass,  with  cyclic  exacerbations 
during menses.  
Transabdominal and transvaginal pelvic ultrasound, with the aid of a color Doppler imaging using a 
high-frequency  probe  (7.5  MHz),  was  performed  for  the  diagnosis  of  a  unilateral  adnexal 
mass (Figure 2).  
The  ultrasonographic  features  showed  cystic  structures  with  low  level  internal  echoes  and 
echogenic wall foci, thickened walls and septations, and percystic color Doppler flow.  
Despite the risk of being a mutation carrier due to the presence of the BRCA1 mutation in her 
mother (Figure 1), the young girl refused oncogenetic counseling and genetic testing. Informed of the 
possible diagnostic strategies, the girl also refused laparoscopic surgery. 
Therefore,  in  order  to  improve  diagnostic  accuracy,  we  suggested  pelvic  magnetic  resonance 
imaging  (MRI)  (Figures  3,  4)  and  determination  of  the  serum  concentrations  of  CA125  and 
HE4 biomarkers.  
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Figure 1. Genealogical diagram of the family with indication of the subjects mutated and 
the type of cancers. 
 
Figure 2. Transvaginal pelvic ultrasound shows cystic structures with low level internal 
echoes and echogenic wall foci, thickened walls and septations.  
 
Single-shot  and  high-spatial-resolution  with  or  without  fat-suppressed  T1  and  T2  weighted 
sequences were performed with a 1.5T Siemens Avanto instrument, which showed several 3 cm cysts 
in the left ovary. They showed a hyperintense signal in the T2-weighted images for the presence of a 
fluid-fluid level and a strong hyperintense signal in the fat suppressed T1-weighted images, typical of 
endometriomas. Furthermore, similar signal characteristics were present in a thin area observed in the 
posterior  uterine  wall,  referred  to  as  an  endometrial  implant.  In  the  lower  part  of  the  cysts,  the 
hypointense T2-weighted images were referred to as blood clots.  
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Figure 3. T2 TSE weighed sequences. Complex images in the left ovary, fluid/fluid level, 
hypointense images in the declive position, axially. 
 
Figure 4. T1 VIBE weighed sequences. Marked hyperintense signal observed in the left 
ovary and a weakly hyperintense thin area is observed in the posterior uterine wall, referred 
to as an endometril implant. 
 
 
Serum  concentrations  of  CA125  and  HE4  were  analyzed  by  ELISA  and,  according  to  the 
manufacturer’s indications, the upper limits for normal values were considered to be 50 pmol/L and 
35 U/mL for HE4, and CA125, respectively. Serum samples were collected both at the time of the 
gynecologic examination and two weeks later (Table 1). Coherent with the MRI finding, the low levels 
of HE4 tentatively indicated a non-malignant type of lesion. 
Table 1. CA125 (expressed as U/mL) and HE4 (expressed as pmol/L) levels, evaluated at 
a two different times (the first at the moment of the gynecologic examination and the 
second two weeks later). 
  Sample 1  Sample 2 
CA 125 (U/mL)  185  330 
HE4 (pmol/L)  44  40 Int. J. Mol. Sci. 2011, 12                       
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This case of a young woman, potentially at genetic risk for breast and ovarian cancer because of her 
family history of breast cancer associated with a BRCA1 mutation, who presented with a pelvic mass 
of uncertain nature, exemplifies the diagnostic challenge that might occur in coping with subjects at 
genetic risk for this type of neoplasia.  
BRCA1 mutation carriers experience a significantly higher probability of developing OC compared 
to the general population [2]. Although our patient had a 50% a priori probability of being a BRCA1 
mutation carrier, due to presence of the familial mutation in her mother, she refused oncogenetic 
counseling and genetic testing, thus limiting our ability to more precisely define her individual risk. 
Therefore, urging the need to pose a correct diagnosis of the pelvic lesion, we approached the case by 
combining  ultrasonography,  MRI  and  determination  of  the  serum  levels  of  HE4  and  CA125 
biomarkers. The high and increasing levels of CA125 and the stably low levels of HE4 together with 
the  features  of  the  lesion  from  the  MRI  imaging  suggested  the  occurrence  of  endometriosis.  A 
laparoscopic study accepted by the patient at a later stage finally confirmed this evaluation. 
A noninvasive means of discriminating between malignant pelvic masses and benign lesions is 
important given that approximately 20% of women will develop an ovarian cyst or pelvic mass at 
some point in their lives. Since serum based assays are noninvasive and relatively inexpensive, it 
would be ideal to have a biomarker or multimarker panel with sufficient sensitivity and specificity, 
which are able to discern the malignant potential that significantly improves differential diagnosis of 
pelvic masses. 
Coupling these markers to techniques such as transvaginal sonography and the more expensive 
MRI increase the overall positive predictive value [10–12]. Based on this experience, we propose that 
determination of HE4 and CA125 serum concentrations together with pelvic ultrasonography and MRI 
may represent a diagnostic strategy for the early diagnosis of ovarian pathologies, in particular for 
individuals  with  a  family  history  of  breast/ovarian  cancers  associated  with  BRCA1/2  mutations, 
integrating previously defined intensified surveillance approaches [2]. Aware of the need to support 
such a proposal with prospective studies, we are planning to set a diagnostic trial to define the real 
cost/benefit  of  combining  pelvic  MRI  and  HE4  and  CA125  serum  determination  in  the  standard 
screening of subject at high-risk for ovarian cancer, such as those with BRCA1 and BRCA2 mutations.  
3. Conclusions 
We conclude that the association of HE4 and CA125 serum concentration may be used to increase 
the  accuracy  in  the  differential  diagnosis  of  pelvic  masses  in  patients  at  high  risk  for 
ovarian neoplasias. 
Acknowledgements 
This  study  is  founded  by  the  University  of  Rome  Sapienza.  We  are  thankful  to  Giuseppina 
Gennarini, Valentina Viggiani, Barbara Colaprisca and Silvestra Tudini for their technical assistance. 
References 
1.  Russo, A.; Calò , V.; Bruno, L.; Rizzo, S.; Bazan, V.; Di Fede, G. Hereditary ovarian cancer.  
Crit. Rev. Oncol. Hematol. 2009, 69, 28–44. Int. J. Mol. Sci. 2011, 12                       
 
632 
2.  Palma, M.; Ristori, E.; Ricevuto, E.; Giannini, G.; Gulino, A. BRAC1 and BRAC2: the genetic 
testing and the current management options for mutation carriers. Crit. Rev. Oncol. Hematol. 
2006, 57, 1–23. 
3.  Schink, J.C. Current initial therapy of stage II and IV ovarian cancer: challenges for managed 
care. Sem. Oncol. 1999, 26, 2–7. 
4.  Hellerstrom, I.; Hellerstron, K.E. SMRP and HE4 as biomarkers for ovarian carcinoma when used 
alone and in combination with CA125 and/or each other. Adv. Exp. Med. Biol. 2008, 622, 15–21. 
5.  Kirchhoff, C. Molecular characterization of epididymal proteins. Rev. Reprod. 1998, 3, 86–95. 
6.  Bingle, L.; Singleton, V.; Bingle, C.D. The putative ovarian tumor marker gene HE4 (WFDC2), is 
expressed in normal tissues and undergoes complex alternative splicing to yeld multiple protein 
isoforms. Oncogene 2002, 21, 2768–2773. 
7.  Clauss,  A.;  Lilja,  H.;  Lundwall,  A.  The  evolution  of  a  genetic  locus  encoding  small  serine 
proteinase inhibitors. Biochem. Biophys. Res. Commun. 2005, 333, 383–389.  
8.  Anastasi, E.; Granato, T.; Marchei, G.G.; Viggiani, V.; Colaprisca, B.; Comploj, S.; Reale, M.G.; 
Frati, L.; Midulla, C. Ovarian tumor marker HE4 is differently expressed during the phases of the 
menstrual cycle in healthy young women. Tumor Biol. 2010, 31, 411–415. 
9.  Anastasi, E.;
 Marchei, G.G.; Viggiani, V.; Gennarini, G.; Frati,
 L.; Reale, M.G. HE4: A new 
potential early biomarker for the recurrence of ovarian cancer. Tumor Biol. 2010, 31, 113–119. 
10.  Chamiè ,  L.P.;  Blasbalg, R.;  Goncalves, M.O.;  Carvalho,  F.M.; Abrao,  M.S.;  de Oliveira,  I.S. 
Accuracy of magnetic resonance imaging for siagnosis and preoperative assessement of deeply 
infiltrating endometriosis. Int. J. Gynecol. Obstet. 2009, 106, 198–201. 
11.  Guerra,  A.;  Cunha,  T.M.;  Fé lix,  A.  Magnetic  resonance  evaluation  of  adnexal  masses.  
Acta Radiol. 2008, 49, 700–709. 
12.  Anderson, G.L.; Mcintosh, M.; Wu, L.; Barnett, M.; Goodman, G.; Thorpe, J.D.; Bergan, L.; 
Thornnquist, M.D.; Scholler, N.; Kim, N.; O’Briant, K.; Drescher, C.; Urban, N. Assessing lead 
time of selected ovarian cancer biomarkers. A nested case-control study. J. Natl. Cancer Inst. 
2010, 102, 26–38. 
© 2011 by the authors; licensee  MDPI, Basel, Switzerland. This  article is  an open  access  article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 